Jesús
San Miguel Izquierdo
Consultor Investigador
Università di Perugia
Perugia, ItaliaPublications in collaboration with researchers from Università di Perugia (5)
2022
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
2021
-
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 11, pp. 785-798
2019
-
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
The Lancet Oncology, Vol. 20, Núm. 6, pp. 781-794
2018
-
Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis
JAMA Oncology, Vol. 4, Núm. 10, pp. 1389-1397
2014
-
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
American Journal of Hematology, Vol. 89, Núm. 4, pp. 355-362